Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 10 (Table of Contents)
Published: 11 Oct-2012
DOI: 10.3833/pdr.v2012.i10.1818 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Roche has licensed global rights to Galaxy Biotech’s preclinical-stage antibodies that target fibroblast growth factor 2 (FGF2), a key target in cancer metastasis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS